The influence of telenzepine on gastrointestinal transit: comparison with placebo and domperidone

Z Gastroenterol. 1990 Feb;28(2):85-9.

Abstract

In a placebo controlled trial, the effect of the M1-antagonist telenzepine (3 mg in the morning) and of the dopamine antagonist domperidone (10 mg t.d.s.) was studied on bowel habits, on oro-caecal and on oro-anal transit time. The study was carried out on healthy subjects double-blind, multiple cross-over. The test periods were seven days each interrupted by wash-out periods of seven days. Stool weight, frequency and consistency as well as side-effects were recorded daily. The oro-anal transit time was estimated by evaluating the excretion of orally ingested radiopaque markers. The oro-caecal transit time was studied by means of a hydrogen breath test after a standard meal. The oro-caecal transit time was significantly prolonged during medication with telenzepine, both compared with placebo (p less than 0.05) and with domperidone (p less than 0.01). Bowel habits and the oro-anal transit time remained statistically unchanged during treatment with the active drugs. It is concluded that telenzepine has a dissociate effect on intestinal motility, delaying transit through the upper gastrointestinal tract without affecting the oro-anal transit time.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Domperidone / pharmacology*
  • Double-Blind Method
  • Female
  • Gastrointestinal Motility / drug effects
  • Gastrointestinal Transit / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Muscle, Smooth / innervation
  • Parasympatholytics / pharmacology*
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / pharmacology
  • Randomized Controlled Trials as Topic
  • Receptors, Dopamine / drug effects
  • Receptors, Muscarinic / drug effects

Substances

  • Parasympatholytics
  • Receptors, Dopamine
  • Receptors, Muscarinic
  • telenzepine
  • Pirenzepine
  • Domperidone